Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

PHASE3CompletedINTERVENTIONAL
Enrollment

395

Participants

Timeline

Start Date

March 17, 2021

Primary Completion Date

November 21, 2023

Study Completion Date

November 21, 2023

Conditions
Asthma
Interventions
BIOLOGICAL

GSK3511294 (Depemokimab)

GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.

DRUG

Placebo

Matching placebo will be administered as a normal saline using a pre-filled syringe.

Trial Locations (123)

10036

GSK Investigational Site, New York

10367

GSK Investigational Site, Berlin

13003

GSK Investigational Site, Marseille

17005

GSK Investigational Site, Girona

18014

GSK Investigational Site, Granada

20122

GSK Investigational Site, Milan

22299

GSK Investigational Site, Hamburg

24127

GSK Investigational Site, Bergamo

24837

GSK Investigational Site, Schleswig

25030

GSK Investigational Site, Besançon

27100

GSK Investigational Site, Pavia

28031

GSK Investigational Site, Madrid

28054

GSK Investigational Site, Gastonia

29631

GSK Investigational Site, Benalmádena

30022

GSK Investigational Site, Alpharetta

30103

GSK Investigational Site, Calhoun

31326

GSK Investigational Site, Columbus

31406

GSK Investigational Site, Savannah

32806

GSK Investigational Site, Orlando

33125

GSK Investigational Site, Miami

33134

GSK Investigational Site, Coral Gables

33144

GSK Investigational Site, Miami

34295

GSK Investigational Site, Montpellier

34655

GSK Investigational Site, New Port Richey

36100

GSK Investigational Site, Vicenza

38010

GSK Investigational Site, Santa Cruz de Tenerife

39120

GSK Investigational Site, Magdeburg

40509

GSK Investigational Site, Lexington

41124

GSK Investigational Site, Modena

42301

GSK Investigational Site, Owensboro

44106

GSK Investigational Site, Cleveland

46015

GSK Investigational Site, Valencia

46017

GSK Investigational Site, Valencia

48507

GSK Investigational Site, Rochester Hills

49300

GSK Investigational Site, Cholet

50333

GSK Investigational Site, Hradec Králové

56068

GSK Investigational Site, Koblenz

60389

GSK Investigational Site, Frankfurt

60549

GSK Investigational Site, Mainz

61761

GSK Investigational Site, Normal

63263

GSK Investigational Site, Neu-Isenburg

63739

GSK Investigational Site, Aschaffenburg

65013

GSK Investigational Site, Tarbes

75235

GSK Investigational Site, Dallas

77099

GSK Investigational Site, Cypress

77429

GSK Investigational Site, Cypress

78006

GSK Investigational Site, Boerne

78028

GSK Investigational Site, Kerrville

78258

GSK Investigational Site, San Antonio

89123

GSK Investigational Site, Las Vegas

90806

GSK Investigational Site, Long Beach

91105

GSK Investigational Site, Pasadena

91730

GSK Investigational Site, Rancho Cucamonga

92024

GSK Investigational Site, Encinitas

95117

GSK Investigational Site, San Jose

110004

GSK Investigational Site, Shenyang

110016

GSK Investigational Site, Shenyang

115093

GSK Investigational Site, Moscow

123995

GSK Investigational Site, Moscow

130021

GSK Investigational Site, Changchun

132011

GSK Investigational Site, Changchun

150047

GSK Investigational Site, Yaroslavl

191025

GSK Investigational Site, Saint Petersburg

193312

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint Petersburg

200040

GSK Investigational Site, Shanghai

200065

GSK Investigational Site, Shanghai

200090

GSK Investigational Site, Shanghai

221006

GSK Investigational Site, Xuzhou

230001

GSK Investigational Site, Hefei

250014

GSK Investigational Site, Jinan

310009

GSK Investigational Site, Hangzhou

325000

GSK Investigational Site, Wenzhou

410013

GSK Investigational Site, Changsha

430030

GSK Investigational Site, Wuhan

500000

GSK Investigational Site, Guangzhou

510115

GSK Investigational Site, Guangzhou

510120

GSK Investigational Site, Guangzhou

510150

GSK Investigational Site, Guangzhou

518020

GSK Investigational Site, Shenzhen

524000

GSK Investigational Site, Zhanjiang

570311

GSK Investigational Site, Sanya

610041

GSK Investigational Site, Chengdu

630008

GSK Investigational Site, Novosibirsk

650002

GSK Investigational Site, Kemerovo

710061

GSK Investigational Site, Xi'an

830054

GSK Investigational Site, Ürümqi

33470-9272

GSK Investigational Site, Loxahatchee Groves

10459-2417

GSK Investigational Site, The Bronx

L1S 2J5

GSK Investigational Site, Ajax

L2H 1H5

GSK Investigational Site, Niagara Falls

K1G 6C6

GSK Investigational Site, Ottawa

N8X 1T3

GSK Investigational Site, Windsor

G1G 3Y8

GSK Investigational Site, Québec

010017

GSK Investigational Site, Hohhot

010050

GSK Investigational Site, Hohhot

625 00

GSK Investigational Site, Brno

377 01

GSK Investigational Site, Jindřichův Hradec

779 00

GSK Investigational Site, Olomouc

386 01

GSK Investigational Site, Strakonice

06001

GSK Investigational Site, Nice

04275

GSK Investigational Site, Leipzig

04357

GSK Investigational Site, Leipzig

00000

GSK Investigational Site, Cork

D09 V2N0

GSK Investigational Site, Dublin

00168

GSK Investigational Site, Roma

25-355

GSK Investigational Site, Kielce

30-033

GSK Investigational Site, Krakow

90-242

GSK Investigational Site, Lodz

20-552

GSK Investigational Site, Lublin

47-120

GSK Investigational Site, Strzelce Opolskie

33-100

GSK Investigational Site, Tarnów

53-201

GSK Investigational Site, Wroclaw

54-239

GSK Investigational Site, Wroclaw

08006

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

07010

GSK Investigational Site, Palma de Mallorca

B9 5SS

GSK Investigational Site, Birmingham

BD9 6RJ

GSK Investigational Site, Bradford

KT16 0PZ

GSK Investigational Site, Chertsey

EC1M 6BQ

GSK Investigational Site, London

M8 5RB

GSK Investigational Site, Manchester

NG5 1PB

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

GlaxoSmithKline

INDUSTRY

NCT04719832 - Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | Biotech Hunter | Biotech Hunter